CJJ300

SKU: orb1687561

Description

CJJ300 is a small molecule TGF-β signaling inhibitor (IC50: 5.3 µM) that acts by disrupting the TGF-β receptor complex formation. This mechanism effectively suppresses downstream signaling, inhibiting cellular processes such as migration in vitro, making it a useful tool for fibrosis, cancer, and developmental biology research.

Research Area

Stem Cell & Developmental Biology

Key Properties

• CAS Number: 1807631-83-9
• MW: 435.6
• Purity: 99.80% (May vary between batches)
• Formula: C₃₀H₃₃N₃
• SMILES: C(NC1=CC=CC=C1)C2=C(C)C(CNC3=CC=CC=C3)=C(C)C(CNC4=CC=CC=C4)=C2C
• Target: TGF-beta/Smad
• Solubility: DMSO:100 mg/mL (229.57 mM);10% DMSO+90% Corn Oil:3.3 mg/mL (7.58 mM)

Bioactivity

• Target IC50:
  TGFβ1:5.3 µM
• In Vitro:
  CJJ300 (20, 40, and 80 µM, 2 h; Human A549 lung epithelial cells) inhibits the phosphorylation of intracellular mediators in the downstream TGF-β signaling pathways, significantly attenuated the increasement of P-Smad2/Smad3, P-Erk1/2, and P-Akt induced by TGF-β. Downregulated the expression of EMT-associated proteins, including fibronectin, α-SMA, and MMP-2 in a dose-dependent manner without cytotoxicity. CJJ300 disturbs protein-protein interactions and prevents TGF-β receptor dimerization (IC50 = 23.6 ± 5.8 µM). CJJ300 suppresses TGF-β induced cell migration.
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Smad, TGFb, TGF-β, TGFβ, TGF-β/Smad, TGF-b/Smad, TGFbeta/Smad, TGF-beta, TGFbeta

Compound Identifiers

PubChem CID

122211714